Registered title, quoted from ClinicalTrials.gov
A Study of Olverembatinib in SDH-deficient GIST.
An open trial on gastrointestinal stromal tumour, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 1 hospital on this site is listed as study site.
Status, phase and start date as registered on ClinicalTrials.gov on 13 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT06640361, read on 13 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 5
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (5 points)Hide the checklist
12 years to Not stated; sex: all
Registered eligibility fields
Negative serum pregnancy test result for women of childbearing potential within 7 days prior to taking the first dose of study drug.
Inclusion criterion 6
Males, women of childbearing potential, as well as their partners, voluntarily take effective contraceptive measures as specified in the protocol from the time of signing the informed consent form until at least 30 days after the last dose of study drug.
Inclusion criterion 7
Received antitumor cytotoxic chemotherapy, radiotherapy, biologic drug therapy, immunotherapy, or other investigational agents within 14 days or less than 5 times the half-life prior to the first dose.
Exclusion criterion 1
Adverse events due to prior treatment have not recovered (> NCI CTCAE v5.0 Grade 1).
Exclusion criterion 4
Major surgery, open biopsy, or major traumatic injury within 14 days prior to initiation of study drug.
Exclusion criterion 10
ECOG≤ 2.
Inclusion criterion 3
Other malignancies within 2 years.
Exclusion criterion 12
Female patients who are pregnant or lactating, or female patients who are expecting to become pregnant within the period of this study.
Exclusion criterion 14
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; blood tests: counts, liver and kidney function; scans and measurable lesions.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06640361, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Histologically and/or cytologically confirmed GIST, immunohistochemistry with loss of SDHB expression, and failure of at least one prior systemic therapy. Defined as disease progression or intolerable as judged by the investigator.
- Must have at least one measurable target lesion.
- ECOG≤ 2.
- Expected survival of at least 3 months.
- Adequate organ function.
- Negative serum pregnancy test result for women of childbearing potential within 7 days prior to taking the first dose of study drug.
- Males, women of childbearing potential, as well as their partners, voluntarily take effective contraceptive measures as specified in the protocol from the time of signing the informed consent form until at least 30 days after the last dose of study drug.
- Prior to initiation of any screening or study-specific procedures, the patient or his/her guardian is able to understand and voluntarily sign an informed consent form approved by the Ethics Committee in writing, voluntarily and able to complete the study procedures and follow-up examinations.
Exclusion Criteria:
- Received antitumor cytotoxic chemotherapy, radiotherapy, biologic drug therapy, immunotherapy, or other investigational agents within 14 days or less than 5 times the half-life prior to the first dose.
- Tyrosine kinase inhibitor (TKI) therapy within 7 days prior to the first dose.
- Use of drugs that have drug interactions with the study drug within 7 days prior to the first dose.
- Adverse events due to prior treatment have not recovered (> NCI CTCAE v5.0 Grade 1).
- Absorption disorder syndrome or other conditions that affect the absorption of oral medications.
- With clinically significant, uncontrolled or active cardiovascular disease or thrombotic disease.
- Poorly controlled hypertension after hypertension medication.
- Severe cardiovascular and cerebrovascular diseases during previous use of TKIs.
- Uncontrolled Hyperlipidemia.
- Major surgery, open biopsy, or major traumatic injury within 14 days prior to initiation of study drug.
- With brain metastases.
- Other malignancies within 2 years.
- Uncontrolled systemic active fungal, bacterial, and/or viral infections.
- Female patients who are pregnant or lactating, or female patients who are expecting to become pregnant within the period of this study.
- Any symptoms or disease of the patient, in the judgment of the investigator or sponsor, that may jeopardize their safety or interfere with the safety evaluation of the investigational drug.
Quoted from ClinicalTrials.gov, NCT06640361, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT06640361, read on 13 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.